Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | MLNR | O43193 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210684 | 0.86 | MAPT (0.43) | SMN1; SMN2POLBHRH3OPRM1OPRK1 | |
| SCHEMBL23210687 | 0.86 | MAPT (0.43) | SMN1; SMN2POLBHRH3OPRM1OPRK1 | |
| SCHEMBL21628808 | 0.85 | HPGD (0.61) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21628806 | 0.85 | HPGD (0.61) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL23210666 | 0.85 | LMNA (0.51) | SMN1; SMN2ALDH1A1POLBHRH3LMNA | |
| SCHEMBL23210665 | 0.85 | LMNA (0.51) | SMN1; SMN2ALDH1A1POLBHRH3LMNA | |
| SCHEMBL21628647 | 0.85 | OPRM1 (0.50) | HRH3OPRM1OPRK1 | |
| SCHEMBL21628648 | 0.85 | OPRM1 (0.50) | HRH3OPRM1OPRK1 | |
| SCHEMBL21628510 | 0.84 | OPRM1 (0.49) | SMN1; SMN2HPGDPOLBHRH3LMNA | |
| SCHEMBL21628508 | 0.84 | OPRM1 (0.49) | SMN1; SMN2HPGDPOLBHRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | SMN1; SMN2 1107/4885ALDH1A1 900/4885HPGD 2313/4885 |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | SMN1; SMN2 796/4885ALDH1A1 717/4885HPGD 2579/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | SMN1; SMN2 796/4885ALDH1A1 717/4885HPGD 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.